2687960-08-1
2687960-08-1
Chemical Structure
Levomefolic acid-13C5
Synonym(s): L-5-MTHF-13C5
- CAS No.: 2687960-08-1
- Formula:C1513C5H25N7O6
- Molecular Weight:464.42
IUPAC Name: (4-((((S)-2-amino-5-methyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzoyl)-L-glutamic-13C5 acid
InChIKey: ZNOVTXRBGFNYRX-MWKWNXLESA-N
SMILES: O=[13C](O)[13CH2][13CH2][13C@@H]([13C](O)=O)NC(C1=CC=C(NC[C@@H]2N(C)C3=C(NC(N)=NC3=O)NC2)C=C1)=O
Biological Activity: Levomefolic acid-13C5 is the 13C labeled Levomefolic acid[1]. Levomefolic acid (L-5-MTHF) is an orally active, brain-penetrant natural active form of folic acid and is one of the most widely used folic acid food supplements[2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Levomefolic acid-13C5 | Levomefolic acid-13C5 is the 13C labeled Levomefolic acid. Levomefolic acid (L-5-MTHF) is an orally active, brain-penetrant natural active form of folic acid and is one of the most widely used folic acid food supplements. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Levomefolic acid-d3 | Levomefolic acid-d3 (L-5-MTHF-d3) is deuterium labeled Levomefolic acid. Levomefolic acid (L-5-MTHF) is an orally active, brain-penetrant natural active form of folic acid and is one of the most widely used folic acid food supplements. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Levomefolic acid-13C,d3 | 98.93% | Levomefolic acid-13C,d3 is the deuterium labeled Levomefolic acid (HY-14781). Levomefolic acid (5-MTHF) is an orally active, brain-penetrant natural active form of folic acid and is one of the most widely used folic acid food supplements. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Levomefolic acid | 98.55% | Levomefolic acid (L-5-MTHF) is an orally active, brain-penetrant natural active form of folic acid and is one of the most widely used folic acid food supplements. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Manisha Prajapat, et al. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. J Mol Graph Model. 2020 Dec;101:107716. [Content Brief]
- [3]. Maša Vidmar Golja, et al. Simultaneous quantification of intracellular concentrations of clinically important metabolites of folate-homocysteine cycle by LC-MS/MS. Anal Biochem. 2020 Sep 15;605:113830. [Content Brief]
